In this article, Dr. Tim Bull breaks down the recently released journal paper from the Crohn’s MAP Vaccine organization, entitled Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. This paper describes the initial safety studies in humans of a vaccine that is designed to stimulate immune recognition of specific components of the MAP bacterium. Dr. Tim Bull is a Reader in Infectious Diseases at St George’s, University of London. He is an internationally recognized expert in mycobacterial diseases and has over 20 years experience in working with culturing mycobacteria. He was instrumental in the initial design and development of the original vaccine and testing the efficacy of a prime-boost version in animals with MAP infection.
Human Paratuberculosis Foundation is dedicated to providing the most up-to-date information in our field to assist patients around the world in making informed decisions about their treatment. We are grateful for the support of this community and look forward to taking this journey together. Read all the latest news and research about mycobacteria, particularly Mycobacterium avium subsp. paratuberculosis (MAP), and the treatment of Crohn’s and immune disease with AMAT and other innovative therapies. Enjoy!